By increasing insulin secretion, inhibiting glucagon, and decreasing the consumption of calories through decreased gastrointestinal motility and central anorectic processes, GLP-1 receptor agonists like semaglutide have anti-obesity benefits. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.